New York A 500: Relates to the compulsory age for full time instruction from six to five years of age and certain exceptions for minor children

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
A00500 Summary:

BILL NOA00500 

&nbsp

SAME ASNo Same As

&nbsp

SPONSORSteck

&nbsp

COSPNSR

&nbsp

MLTSPNSR

&nbsp

Add Art 2-A Title IV §§285 - 288, Pub Health L

&nbsp

Establishes a generic drug research and development laboratory and production facility to manufacture generic prescription drugs in the state and the empire state biosimilar insulin initiative, which will develop generic forms of the three most widely used forms of insulin.

Go to top A00500 Actions:

BILL NOA00500 

&nbsp

01/08/2025referred to health

01/07/2026referred to health

Go to topA00500 Committee&nbspVotes:

Go to topA00500 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topA00500 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 500

 2025-2026 Regular Sessions

 IN ASSEMBLY

 (Prefiled)

 January 8, 2025
 ___________

 Introduced by M. of A. STECK -- read once and referred to the Committee
 on Health

 AN ACT to amend the public health law, in relation to establishing a
 generic drug research and development laboratory and production facil-
 ity and the empire state biosimilar insulin initiative

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Article 2-A of the public health law is amended by adding a
 2 new title IV to read as follows:
 3 TITLE IV
 4 NEW YORK AFFORDABLE DRUG MANUFACTURING ACT
 5 Section 285. Definitions.
 6 286. Generic drug research and development laboratory and
 7 production facility; empire state biosimilar insulin
 8 initiative.
 9 287. Partnerships; production and distribution of prescription
 10 drugs.
 11 288. Proprietary information.
 12 § 285. Definitions. 1. For the purposes of this title, the following
 13 terms shall have the following meanings:
 14 (a) "Generic drug" shall mean a drug that is approved pursuant to
 15 subdivision (j) of section 355 of the Federal Food, Drug, and Cosmetic
 16 Act (21 U.S.C. Sec. 301 et seq.), or a biosimilar, as defined under the
 17 federal Public Health Service Act (42 U.S.C. Sec. 262).
 18 (b) "Partnerships" shall include, but not be limited to, agreements
 19 for the procurement of generic prescription drugs by way of contracts or
 20 purchasing by a payer, state governmental agency, group purchasing
 21 organization, nonprofit organization, or other entity.
 22 § 286. Generic drug research and development laboratory and production
 23 facility; empire state biosimilar insulin initiative. 1. (a) The depart-

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD00670-01-5

 A. 500 2

 1 ment shall establish a generic drug research and development laboratory
 2 and production facility within the university of the state of New York
 3 system.
 4 (b) The generic drug research and development laboratory and
 5 production facility established pursuant to paragraph (a) of this subdi-
 6 vision shall produce and distribute generic prescription drugs, with the
 7 intent that these drugs be made widely available to public and private
 8 purchasers, facilities licensed pursuant to article twenty-eight of this
 9 chapter, and pharmacies as defined in section six thousand eight hundred
 10 two of the education law, as appropriate.
 11 (c) Each drug produced pursuant to paragraph (b) of this subdivision
 12 shall be made available to providers, patients, and purchasers at a
 13 price not to exceed the cost of such production for residents of the
 14 state.
 15 (d) The department shall prioritize the development and production of
 16 generic prescription drugs that have the greatest impact on lowering
 17 drug costs to patients, increasing competition and addressing shortages
 18 in the prescription drug market, improving public health, or reducing
 19 the cost of prescription drugs to public and private purchasers.
 20 2. The first initiative of the generic drug research and development
 21 laboratory and production facility established pursuant to subdivision
 22 one of this section shall be the empire state biosimilar insulin initi-
 23 ative. Such initiative shall include the research, development, and
 24 production of generic forms of the three most widely used forms of insu-
 25 lin. Such insulin sh